Reduced prefrontal cortex DARPP-32 mRNA in completed suicide victims with schizophrenia

Schizophrenia Research

Volumn 103, Issue 1-3, 2008, Pages 192-200

  Feldcamp, Laura A ^a   Souza, Renan P ^b   Romano Silva, Marco ^c   Kennedy, James L ^a   Wong, Albert H C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Faculdade de Medicina   (Brazil)

Author keywords

Brodmann Area 46; DARPP 32; rs907094; rs9532; Schizophrenia; Suicide

Indexed keywords

CYCLOPHILIN; MESSENGER RNA; PHOSPHOPROTEIN DARPP 32;

ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HOUSEKEEPING GENE; HUMAN; HUMAN TISSUE; NEGATIVE SYNDROME; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDE; VICTIM;

ADULT; CHROMOSOMES, HUMAN, PAIR 17; CYCLOPHILINS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; FEMALE; GENOTYPE; HUMANS; INTRONS; LINKAGE DISEQUILIBRIUM; MALE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREFRONTAL CORTEX; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCHIZOPHRENIA; SUICIDE;

EID: 47249145953     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.05.014     Document Type: Article

References (33)

1. Albert K.A., Hemmings H.C., Adamo A.I., Potkin S.G., Akbarian S., Sandman C.A., Cotman C.W., Bunney W.E., and Greengard P. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch. Gen. Psychiatry 59 (2002) 705-712
2. Alt A., Nisenbaum E.S., Bleakman D., and Witkin J.M. A role for AMPA receptors in mood disorders. Biochem. Pharmacol. 71 (2006) 1273-1288
3. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotypes maps. Bioinformatics 21 (2005) 263-265
4. De Luca V., Likhodi O., Van Tol H.H.M., Kennedy J.L., and Wong A.H.C. Tryptophan hydroxylase 2 gene expression and promoter polymorphisms in bipolar disorder and schizophrenia. Psychopharmacology 83 3 (2005) 378-382
5. De Luca V., Likhodi O., Kennedy J.L., and Wong A.H.C. Parent-of-origin effect and genomic imprinting of the HTR2A receptor gene T102C polymorphism in psychosis. Psychiatry Res. 151 (2007) 243-248
6. De Luca V., Likhodi O., Kennedy J.L., and Wong A.H.C. Differential expression and parent of origin effect of the 5-HT2a receptor gene C102T polymorphism: analysis of suicidality in schizophrenia and bipolar disorder. Am. J. Med. Gen. Part B. Neuropsychiatr. Genet. 144 3 (2007) 370-374
7. Dhir A., and Kulkarni S.K. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (σ) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist. Brain Res. Bullet. 74 (2007) 58-65
8. Di Mascio M., and Esposito E. The degree of inhibition of dopaminergic neurons in the ventral tegmental area induced by selective serotonin reuptake inhibitors is a function of the density-power-spectrum of the interspike interval. Neuroscience 79 (1997) 957-961
9. Fernandez E., Schiappa R., Girault J.A., and Le Novere N. DARPP-32 is a robust integrator of dopamine and glutamate signals. PLOS Comput. Biol. 2 (2006) 1619-1633
10. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., Higgins J., DeFelice M., Loch A., Faggart M., Liu Cordero S.N., Rotimi C., Adeyemo A., Cooper R., Ward R., Lander E.S., Daly M.J., and Altshuler D. The structure of haplotypes blocks in the human genome. Science 296 (2002) 2225-2229
11. Greengard P. The neurobiology of slow synaptic transmission. Science 294 5544 (2001) 1024-1030
12. Higgs B.W., Elashoff M., Richman S., and Barci B. An online database for brain disease research. BMC Genomics 7 (2006) 70-87. http://www.stanleyresearch.org/brain/ SMRI website: http://www.stanleyresearch.org/brain/
13. Ishikawa M., Mizukami K., Iwakiri M., and Asada T. Immunohistochemical and immunoblot analysis of dopamine and cyclicAMP-regulated phosphoprotein, relative mass 32,000 (DARPP-32) in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 31 (2007) 1177-1181
14. Li C.H., Liao H.M., Hung T.W., and Chen C.H. Mutation analysis of DARPP-32 as a candidate gene for schizophrenia. Schizophrenia Res. 87 (2006) 1-5
15. Laje G., Paddock S., Manji H., Rush A.J., Wilson A.F., Charney D., and McMahon F.J. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am. J. Psychiatry 164 10 (2007) 1530-1538
16. Mann J.J. Neurobiology of suicidal behaviour. Nat. Rev. Neurosci. 4 10 (2003) 819-828
17. Mann J.J., Brent D.A., and Arango V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology 24 5 (2001) 467-477
18. Meyer-Lindenberg A., Straub R.E., Lipska B.K., Verchinski B.A., Goldberg T., Callicott J.H., Egan M.F., Huffaker S.S., Mattay V.S., Kolachana B., Kleinman J.E., and Weinberger D.R. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J. Clin. Investigation 117 (2007) 672-682
19. Muñoz, A., Lopez-Real, A., Labandeira-Garcia, J.L., Guerra, M.J., 2003. Interaction between the noradrenergic and serotonergic systems in locomotor hyperactivity and striatal expression of Fos induced by amphetamine in rats. Exp. Brain Res. 153 (1), 92-99.
20. 11C]raclopride. Int. J. Neuropsychopharmacol. 7 (2004) 431-439
21. Polesskaya O.O., and Sokolov B.P. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J. Neurosci. Res. 67 (2002) 812-822
22. Radomsky E.D., Haas G.L., Mann J.J., and Sweeny J.A. Suicidal behavior in patients with schizophrenia and other psychotic disorders. Am. J. Psychiatry 156 10 (1999) 1590-1595
23. Reis, H.J., Rosa, D.V., Guimarães, M.M., Souza, B.R., Barros, A.G., Pimenta, F.J., Souza, R.P., Torres, K.C., Romano-Silva, M.A., 2007. Is DARPP-32 a potential therapeutic target? Expert Opin. Ther. Targets 11 (12), 1649-1661.
24. Ross C.A., Margolis R.L., Reading S.A., Pletnikov M., and Coyle J.T. Neurobiology of schizophrenia. Neuron 52 1 (2006) 139-153
25. Sekine Y., Suzuki K., Ramachandran P.V., Blackburn T.P., and Ashby C.R. Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse 61 (2007) 72-77
26. Siris S.G., Addington D., Azorin J., Falloon I., Gerlach J., and Hirsch S. Depression in schizophrenia: recognition and management in the USA. Schizophrenia Res. 47 (2001) 185-197
27. Souza B.R., Motta B.S., Rosa D.V.F., Torres K.C.L., Castro A.A., Comim C.M., Sampaio A.M., Lima F., Jeromin A., Quevedo J., and Romano-Silva M.A. DARPP-32 and NCS-1 expression is not altered in brains of rats treated with typical or atypical antipsychotics. Neurochem. Res. (2007) Aug 31, [Electronic publication ahead of print]
28. Svenningsson P., Tzavara E.T., Witkin J.M., Fienberg A.A., Nomikos G.G., and Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). P.N.A.S. USA 99 (2002) 3182-3187
29. Svenningsson P., Tzavara E.T., Liu F., Fienberg A.A., Nomikos G.G., and Greengard P. DARPP-32 mediates serotonergic neurotransmission in the forebrain. P.N.A.S. USA 99 (2002) 3188-3193
30. Svenningsson P., Nishi A., Fisone G., Girault J.A., Nairn A.C., and Greengard P. DARPP-32: an integrator of neurotransmission. Ann. Rev. Pharmacol. Toxicol. 44 (2004) 269-296
31. Svenningsson P., Nairn A.C., and Greengard P. DARPP-32 mediates the actions of multiple drugs of abuse. A.A.P.S. J. 7 2 (2005) E353-E360
32. Wong A.H., and Van Tol H.H.M. Schizophrenia: from phenomenology to neurobiology. Neurosci. Biobehav. Rev. 27 3 (2003) 269-306
33. Yoshimi A., Takahashi N., Saito S., Ito Y., Aleksic B., Usui H., Kawamura Y., Waki Y., Yoshikawa T., Kato T., Iwata N., Inada T., Noda Y., and Ozaki N. Genetic analysis of the gene coding for DARPP-32 (PPP1R1B) in Japanese patients with schizophrenia or bipolar disorder. Schizophren Res. 100 (2008) 334-341